Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals

Clinical Drug Investigation

Volumn 23, Issue 10, 2003, Pages 629-637

  De Maat, Monique M R ^a   Huitema, Alwin D R ^a   Mulder, Jan W ^a   Meenhorst, Pieter L ^a   Van Gorp, Eric C M ^a   Mairuhu, Albert T A ^a   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; FLUOXETINE; FLUVOXAMINE; NEVIRAPINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 0142074300     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323100-00002     Document Type: Article

References (31)

1. Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry 2001; 158: 725-30
2. Penzak SR, Reddy YS, Grimsley SR. Depression in patients with HIV infection. Am J Health Syst Pharm 2000; 57: 376-86
3. Cohen M, Hoffman RG, Cromwell C, et al. The prevalence of distress in persons with human immunodeficiency virus infection. Psychosomatics 2002; 43: 10-5
4. Schulz RM, Mullenix TA, Googe HL, et al. Depression scores and antiretroviral therapy adherence in HIV disease [abstract 1-215]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Dec 16-19; Chicago (IL). Washington, DC: American Society for Microbiology 20005, 1998
5. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30
6. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28
7. Smith PF, Dicenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001; 40: 893-905
8. Sommadossi J-P. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS 1999; 13 Suppl. 1: S29-40
9. DeSilva KE, Le Flore DB, Marston BJ, et al. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15: 1281-5
10. Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27: 1488-95
11. Lamson M, MacGregor T, Riska P, et al. Nevirapine induces both CYP3A4 and CYP2B6 metabolic pathways [abstract]. Clin Pharmacol Ther 1999; 65: 137
12. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46: 35-9
13. Von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-31
14. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31
15. De Maat MMR, Huitema ADR, Mulder JW, et al. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54: 378-85
16. Van Heeswijk RPG, Hoetelmans RMW, Meenhorst PL, et al. Rapid determination of nevirapine in human plasma by ion-pair reversed phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998; 713: 395-9
17. Beal SL, Sheiner LB. NONMEM user's guide. University of California at San Francisco: NONMEM Project Group, 1998
18. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-8
19. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-14
20. Liu Z-Q, Zhu B, Tan Y-F, et al. O-dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther 2001; 299: 105-11
21. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44: 190-4
22. Murphy RL, Sommadossi J-P, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179: 1116-23
23. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-69
24. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29: 1-9
25. Carillo JA, Dahl M-L, Svensson J-O, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 183: 183-90
26. Kumar AM, Berger JR, Eisdorfer C, et al. Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. Neuropsychobiology 2001; 44: 13-8
27. Dursun SM, Reveley MA. Serotonin hypothesis of psychiatric disorders during HIV infection. Med Hypotheses 1995; 44: 263-7
28. Eriksson T, Lidberg L. Decreased plasma ratio of tryptophan to competing large neutral amino acids in human immunodeficiency virus type 1 infected subjects: possible implications of neuro-psychiatric disorders. J Neural Transm 1996; 103: 157-64
29. Fuchs D, Moller AA, Reibnegger G, et al. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873-6
30. González de Requena D, Núñez M, et al. Liver toxicity caused by nevirapine. AIDS 2002; 16: 290-1
31. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512-21